Galecto, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

19 Mar 2026

GLTO

10-K: Damora Therapeutics 2025 Annual: Pipeline Focus & Capital

Damora Therapeutics' 2025 annual report details a strategic pivot to mutCALR MPN therapies, significant capital raises, and ongoing preclinical development amidst substantial operating losses.

19 Mar 2025

GLTO

Galecto, INC

10-K: Galecto Focuses on Oncology and Liver Diseases After Strategic Review, Reports Going Concern Uncertainty

Galecto's 10-K filing reveals a strategic shift towards oncology and liver diseases, alongside concerns about its ability to continue as a going concern due to recurring losses and the need for additional funding.

8 Mar 2024

GLTO

Galecto, INC

10-K: Galecto Outlines Capital Stock Structure and Strategic Review Process in 10-K Filing

Galecto's 10-K filing details its capital stock structure, ongoing strategic review, and the potential for strategic transactions.